Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Arbutus Biopharma logo
$4.20 -0.01 (-0.24%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$4.22 +0.01 (+0.36%)
As of 10/23/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Advanced

Key Stats

Today's Range
$4.12
▼
$4.22
50-Day Range
$4.11
▼
$5.21
52-Week Range
$3.50
▼
$5.45
Volume
2.03 million shs
Average Volume
7.00 million shs
Market Capitalization
$832.06 million
P/E Ratio
5.32
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Moderate Buy

Company Overview

Arbutus Biopharma Corporation is a biopharmaceutical company focused on developing novel therapies for chronic hepatitis B virus (HBV) infection. Its research is aimed at addressing multiple stages of the HBV lifecycle, with the long-term goal of developing functional cures rather than therapies that only suppress the virus.

The company’s pipeline has included investigational medicines such as AB-729, an RNA interference therapeutic designed to reduce hepatitis B surface antigen, and other antiviral candidates intended to inhibit viral replication. Arbutus has also developed expertise in lipid nanoparticle delivery technology, which is used to help deliver nucleic acid-based medicines into cells.

Arbutus traces its corporate history to Tekmira Pharmaceuticals and adopted the Arbutus Biopharma name in 2015. The company is headquartered in Warminster, Pennsylvania, and its shares trade on the Nasdaq under the symbol ABUS. William R. Collier has served as the company’s president and chief executive officer.

AI Generated. May Contain Errors.

Arbutus Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

ABUS MarketRank™: 
2.59388412017 of 5 stars

Arbutus Biopharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 480th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arbutus Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    Arbutus Biopharma has a consensus price target of $5.00, representing about 19.0% upside from its current price of $4.20.

  • Amount of Analyst Coverage

    Arbutus Biopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Arbutus Biopharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arbutus Biopharma is 5.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arbutus Biopharma is 5.32, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.

  • Price to Book Value per Share Ratio

    Arbutus Biopharma has a P/B Ratio of 10.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arbutus Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    21.46% of the float of Arbutus Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Arbutus Biopharma has a short interest ratio ("days to cover") of 3.53, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arbutus Biopharma has recently increased by 84.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arbutus Biopharma does not currently pay a dividend.

  • Dividend Growth

    Arbutus Biopharma does not have a long track record of dividend growth.

  • News Sentiment

    Arbutus Biopharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.90% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arbutus Biopharma's insider trading history.
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABUS Stock News Headlines

Arbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B Drug
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon. A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years.tc pixel
See More Headlines

ABUS Stock Analysis - Frequently Asked Questions

Arbutus Biopharma's stock was trading at $4.81 on January 1st, 2026. Since then, ABUS shares have decreased by 12.7% and is now trading at $4.20.

Arbutus Biopharma Corporation (NASDAQ:ABUS) released its earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The biopharmaceutical company earned $1.01 million during the quarter, compared to analyst estimates of $0.70 million. Arbutus Biopharma had a net margin of 84.22% and a trailing twelve-month return on equity of 90.98%.

Arbutus Biopharma's Board of Directors approved a stock buyback plan on Friday, August 21st 2026, which allows the company to repurchase $0 in shares, according to EventVestor. This allows the company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board believes its stock is undervalued.

Arbutus Biopharma's top institutional shareholders include Two Seas Capital LP (4.11%), Assenagon Asset Management S.A. (0.31%), SBI Securities Co. Ltd. (0.01%) and State of Alaska Department of Revenue (0.01%).
View institutional ownership trends
.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Tesla (tsla), NIO (NIO), Sorrento Therapeutics (SRNE), Plug Power (PLUG), Moderna (MRNA), Inovio Pharmaceuticals (INO) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/13/2026
Today
10/25/2026
Next Earnings (Estimated)
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ABUS
CIK
1447028
Employees
19
Year Founded
2005

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+19.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.79
Trailing P/E Ratio
5.32
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$33.50 million
Net Margins
84.22%
Pretax Margin
84.22%
Return on Equity
90.98%
Return on Assets
82.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
81.42
Quick Ratio
81.42

Sales & Book Value

Annual Sales
$14.08 million
Price / Sales
59.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.40 per share
Price / Book
10.50

Miscellaneous

Outstanding Shares
198,110,000
Free Float
158,683,000
Market Cap
$832.06 million
Optionable
Optionable
Beta
0.76

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:ABUS) was last updated on 10/23/2026 by MarketBeat.com Staff.
From Our Partners